274. Osteogenesis Imperfecta Clinical trials / Disease details


Clinical trials : 87 Drugs : 103 - (DrugBank : 20) / Drug target genes : 14 - Drug target pathways : 76

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-005275-42-IT
(EUCTR)
21/03/200523/01/2008Study on the effect of r-hGH in combination with bisphosphonate treatment on bone metabolism in Osteogenesis ImperfectaStudy on the effect of r-hGH in combination with bisphosphonate treatment on bone metabolism in Osteogenesis Imperfecta Osteogenesis Imperfecta
MedDRA version: 6.1;Level: SOC;Classification code 10010331
Trade Name: GENOTROPIN*1TBF 5,3MG (16UI)
INN or Proposed INN: Somatropin
Trade Name: NERIXIA*INFUS IV CONC 2F 100MG
INN or Proposed INN: VARI
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONANULLNot RecruitingFemale: yes
Male: yes
Italy
2NCT00001305
(ClinicalTrials.gov)
November 5, 19913/11/1999Growth Hormone Therapy in Osteogenesis ImperfectaStudies of Growth Deficiency and Growth Hormone Treatment in Children With Osteogenesis Imperfecta Types III and IVOsteogenesis ImperfectaDrug: HumatropeEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NULLCompleted3 Years16 YearsAll42Phase 3United States